Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Abroad (travel likely)RecruitingPHASE1
Conditions
EGFR Mutation Positive Non-small Cell Lung Cancer · EGFR Mutated Non-small Cell Lung Cancer Patients
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Maryland Oncology Hematology, Calverton, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
NEXT Houston, Houston, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Study leads
Zofia Piotrowska, MD, MHS
Principal Investigator
Massachusetts General Hospital